Clinical Trials in Genitourinary Cancers: MAGNITUDE, PROOF 302, and CYTOSHRINK

December 21, 2020
Brielle Gregory, ASCO staff

Clinical trials are the main way that doctors are able to find better treatment for diseases like cancer. Active clinical trials are exploring possible new cancer treatments and ways to prevent or reduce side effects. In this podcast series, members of the Cancer.Net Editorial Board share their expert opinions about ongoing clinical trials that are studying genitourinary (GU) cancers.

In this podcast, Timothy Gilligan, MD, FASCO, leads a discussion with Neeraj Agarwal, MD; Brian Shuch, MD; and Tian Zhang, MD, about 3 clinical trials in prostate cancer, bladder cancer, and kidney cancer.

Dr. Gilligan is a medical oncologist at the Cleveland Clinic Taussig Cancer Institute and a Cancer.Net Specialty Editor for Genitourinary Cancers. Dr. Agarwal directs the Genitourinary Oncology Program at the Huntsman Cancer Institute at the University of Utah and is a Cancer.Net Specialty Editor for Genitourinary Cancers. Dr. Shuch is the director of the Kidney Cancer Program at UCLA Health, the Alvin & Carrie Meinhardt Endowed Chair in Kidney Cancer Research at the institution, and a Cancer.Net Specialty Editor for Genitourinary Cancers. Dr. Zhang is an assistant professor of medicine at Duke University School of Medicine, a medical oncologist at Duke Cancer Institute, and a Cancer.Net Specialty Editor for Genitourinary Cancers.

Disclosure information for this podcast’s speakers can be found in their individual biographies, which are linked in the paragraph above.

Was this podcast useful? Please subscribe, rate, and review Cancer.Net Podcasts on Apple Podcasts or Google Play. This prerecorded podcast can be listened to online or downloaded to your computer. A transcript is also available. For more information, visit the Cancer.Net podcast page.

Cancer.Net podcasts are edited for length and content. 

Share your thoughts on this blog post on Cancer.Net's Facebook and Twitter.